Aetna Facial Feminization Second Circuit Appeal: Insurer Fights Discrimination Ruling

• Aetna is appealing a federal judge's ruling that found its automatic denial of facial feminization surgery (FFS) for transgender patients to be discriminatory.
• The initial ruling by U.S. District Judge Victor Bolden mandated individualized medical reviews for FFS under the Affordable Care Act's anti-discrimination provisions.
• Aetna argues that plaintiffs' claims stem from employer-designed health plans, not Aetna's guidelines, and questions the medical necessity of FFS.
• Plaintiffs contend Aetna creates an unfair barrier for transgender women by denying individualized reviews for FFS, unlike for cisgender individuals seeking similar procedures.
• The Second Circuit's decision will significantly impact how insurers define 'medical necessity' for gender-affirming care and interpret ACA anti-discrimination rules for employer-sponsored plans.

The outcome could necessitate a re-evaluation of current health plan coverage policies for transgender individuals across the industry.

Health insurance giant Aetna is currently appealing a federal judge's decision that found its policy of automatically denying coverage for facial feminization surgery (FFS) to transgender patients discriminatory. The appeal, heard by the Second Circuit, centers on a class action lawsuit filed in Connecticut federal court in 2024 by a group of transgender women. These plaintiffs contend that Aetna improperly classified their FFS procedures—which involve structural bone modifications and the readaptation of overlying soft tissues as part of gender-affirming care—as excluded "cosmetic surgeries," thereby refusing to cover the associated costs.

U.S. District Judge Victor Bolden, an appointee of former President Barack Obama, ruled in March that Aetna's blanket refusal to fund FFS for treating gender dysphoria violated the Affordable Care Act's (ACA) prohibitions against sex-based discrimination in federally funded healthcare programs. As part of a preliminary injunction, Judge Bolden mandated that Aetna conduct individualized medical reviews for the transgender women seeking these procedures. This pivotal ruling, which Aetna now seeks to overturn, has brought the insurer's practices regarding gender-affirming care under intense scrutiny, particularly concerning the Aetna facial feminization Second Circuit appeal.

Aetna, a subsidiary of CVS Health Corporation and the nation's second-largest health insurance company, argues that the district court's ruling should be reversed. The insurer contends that any alleged injuries suffered by the plaintiffs are attributable to their employers' health plan designs, rather than to Aetna's advisory guidelines or coverage policies. While Aetna asserts it covers a wide array of treatments for gender dysphoria, it maintains that current medical and scientific evidence does not sufficiently demonstrate the effectiveness and medical necessity of certain facial surgeries for alleviating gender dysphoria symptoms.

During the Second Circuit proceedings, Aetna's attorney, Charles McCloud, asserted that the plaintiffs' standing is compromised because they sued Aetna, which administers benefits, instead of their employers, who ultimately control the design of their health insurance plans and dictate which treatments are reimbursed. McCloud emphasized that if Aetna were to unilaterally authorize treatments not covered by employer benefit plans, the employers would not be obligated to provide reimbursement. This argument highlights a key aspect of transgender healthcare ERISA plans, suggesting that Aetna believes it cannot be compelled to cover services that employers have not agreed to fund, as neither the district court nor the appeals court could remedy injuries by ordering Aetna to take steps that employers could simply thwart or override.

The Second Circuit judges rigorously questioned the arguments presented. U.S. Circuit Judge Matthew Schwartz, a Donald Trump appointee, probed Aetna's position by asking if the insurer would cover FFS for a "biological woman" seeking to appear more feminine. McCloud responded that such a procedure would be deemed cosmetic regardless of gender identity, but could be covered if there was a "qualifying medical diagnosis." This exchange underscored the differing standards applied to various patient groups seeking similar procedures.

In response, Kelly Parry-Johnson, the attorney for the plaintiffs, countered that Aetna's policies create an additional barrier for transgender individuals seeking care that is not imposed on cisgender people pursuing similar procedures. She highlighted that Aetna would, at minimum, conduct an individualized medical necessity review for a non-transgender woman, whereas a transgender woman seeking facial feminization surgery coverage faces an automatic denial. U.S. Circuit Judge Debra Ann Livingston, who assumed senior status on July 1, 2026, a George W. Bush appointee, pressed Parry-Johnson on whether a categorical determination that a treatment for gender dysphoria is not medically necessary, without individualized review, inherently raises a strong inference of discrimination. Parry-Johnson affirmed that it would indeed raise such an inference, noting further that the specific exclusion text in question does not rely on a diagnosis, reinforcing the argument of disparate treatment in this Aetna gender-affirming care lawsuit.

This ongoing legal battle holds significant implications for the landscape of gender-affirming care and how health insurers define medical necessity. The Second Circuit's eventual ruling in this case will shape how health insurers, including those administering transgender healthcare ERISA plans, can interpret and apply their coverage policies, particularly concerning the ACA sex discrimination health insurance provisions. The core issue revolves around whether a blanket denial of a specific gender-affirming procedure, like FFS, constitutes unlawful discrimination when other treatments for gender dysphoria are covered and when similar procedures might be reviewed individually for cisgender patients.

The outcome could necessitate a re-evaluation of current health plan coverage policies for transgender individuals across the industry. It will provide crucial clarity on the extent to which insurers must conduct individualized assessments for gender-affirming treatments, rather than relying on categorical exclusions, thereby influencing future Second Circuit gender dysphoria ruling precedents.

Lawyers and compliance officers should closely monitor the Second Circuit's decision in this case, as it will significantly impact how health insurers can define 'medical necessity' for gender-affirming care and the extent of their liability under the Affordable Care Act's anti-discrimination provisions, especially when employer-sponsored plans are involved. This ruling could necessitate a review of current health plan coverage policies for transgender individuals.

Source: Original reporting via Courthouse News Service